Immuron Limited Warrants
Immuron Limited Warrants
Your view on IMRNW
Overview
What the company does, where it operates, and who runs it.
About Immuron Limited Warrants
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Not available
- Headquarters
- US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Not available
- Headquarters
- US
Immuron Limited, an Australian biopharmaceutical firm headquartered in Carlton and founded in 1994, is dedicated to the research, development, and market introduction of polyclonal antibodies. The company maintains a global presence, conducting operations across Australia, Israel, Canada, the United States, and other international territories. Its business activities are segmented into two core areas: Research and Development, and Hyperimmune Products. Immuron currently offers two main products: Travelan: An over-the-counter medication designed to mitigate the risk of travelers’ diarrhea and minor gastrointestinal discomfort. It also functions as a dietary supplement that supports digestive health and protects the gastrointestinal tract. Protectyn: An immune supplement aimed at fostering healthy digestive function and supporting liver vitality. In its development pipeline, Immuron is advancing several candidates: Travelan (IMM-124E): This version is specifically being developed for the U.S. market to reduce the risk of contracting travelers’ diarrhea. IMM-529: A therapeutic treatment for individuals experiencing recurring Clostridium difficile infections. The company has also established strategic collaborations, including a research agreement with the Naval Medical Research Center focused on developing and clinically evaluating a treatment for Campylobacter and enterotoxigenic Escherichia coli infections. Additionally, Immuron holds a collaborative agreement with the Walter Reed Army Institute of Research to create an oral therapeutic specifically for shigellosis.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Immuron Limited Warrants, and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Immuron Limited Warrants. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Immuron Limited Warrants. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Immuron Limited Warrants. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Immuron Limited Warrants. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Immuron Limited Warrants valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Immuron Limited Warrants, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Immuron Limited Warrants executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Immuron Limited Warrants. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Immuron Limited Warrants. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Immuron Limited Warrants. Press releases and market coverage, newest first.